Zhao Yan, Sun Hongli, Feng Minjuan, Zhao Jinyan, Zhao Xiaogui, Wan Qiuyuan, Cai Dongge
a Department of Obstetrics and Gynecology , The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an , Shaanxi , PR China.
b Shaanxi Institute of Pediatric Diseases , The Affiliated children's hospital of Xi'an Jiaotong University , Xi'an , Shaanxi , PR China.
Gynecol Endocrinol. 2018 May;34(5):428-432. doi: 10.1080/09513590.2017.1409714. Epub 2017 Nov 28.
Metformin recently gained traction as potential anti-endometrial cancer agent for its new applications. However, the underlying mechanisms of the anti-cancer effect of metformin in the endometrial cancer have not yet been fully elucidated. Sixty-five patients diagnosed as endometrial carcinoma were grouped into (n = 33) and non-treatment mixed (n = 32) for analysis. Thirty healthy donors were recruited as controls. We attempt to investigate the effect of metformin on Ki-67, PI3K, p-AKT, p-S6K1, and p-4EBP1 staining in human endometrial cancer by immunohistochemical staining. We found that increased Ki-67 expression in women with endometrial cancer, which were reversed by conventional anti-diabetic doses of metformin in present work. In parallel, the reduced PI3K, p-AKT, p-S6K1, and p-4EBP1 staining induced by metformin appeared to play an important role for the anti-proliferative effects of metformin in endometrial cancer patients. Metformin significantly decreased proliferation in human endometrial cancer may by inhibiting PI3K/AKT/mTOR signaling. Our present results add to the growing body of evidence supporting metformin as a potential anti-cancer agent in endometrial cancer.
二甲双胍因其新的应用，最近作为潜在的抗子宫内膜癌药物受到关注。然而，二甲双胍在子宫内膜癌中的抗癌作用的潜在机制尚未完全阐明。将65例诊断为子宫内膜癌的患者分为治疗组（n = 33）和未治疗混合组（n = 32）进行分析。招募30名健康供者作为对照。我们试图通过免疫组织化学染色研究二甲双胍对人子宫内膜癌中Ki-67、PI3K、p-AKT、p-S6K1和p-4EBP1染色的影响。我们发现，在本研究中，子宫内膜癌女性中Ki-67表达增加，而常规抗糖尿病剂量的二甲双胍可使其逆转。同时，二甲双胍诱导的PI3K、p-AKT、p-S6K1和p-4EBP1染色减少似乎对二甲双胍在子宫内膜癌患者中的抗增殖作用起重要作用。二甲双胍可能通过抑制PI3K/AKT/mTOR信号通路显著降低人子宫内膜癌的增殖。我们目前的结果增加了越来越多的证据，支持二甲双胍作为子宫内膜癌的潜在抗癌药物。
